Caszyme and Integra Therapeutics sign licensing agreement for novel CRISPR Cas12l nucleases

Caszyme and Integra Therapeutics

Caszyme, a pioneer in the development and application of CRISPR gene editing technology, and Integra Therapeutics, a company leading the way in creating advanced therapies based on next-generation gene-writing tools, today announced a licensing agreement for the use of Caszyme’s novel Cas12l nucleases to develop safer and more efficient gene and cell therapies. The agreement […]